Date: 2014-12-22
Type of information: R&D agreement
Compound:
Company: Eli Lilly (USA - IN) University of Surrey (UK)
Therapeutic area: Metabolic diseases
Type agreement: R&D
Action mechanism:
Disease: type 2 diabetes
Details: * On December 22, 2014, Eli Lilly announced a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes. Using real-world evidence (routine data gathered from patients undergoing diabetes treatments), Lilly and the University of Surrey will focus on developing answers to commonly asked clinical questions about the continuum of diabetes care, such as the role and timing of injectable therapy, factors impacting adherence to prescribed medicines and the pattern and rationale of therapy following diagnosis. Initially the Lilly-Surrey collaboration will focus on some key questions: Adherence to therapy: Why do some people follow their diabetes treatment plan while others do not? What role do healthcare providers play in improving adherence rates? What are the barriers and the long-term effects for those who do not adhere to their treatment?
Triggers for initiation of injectable therapy: People with type 2 diabetes often transition to different therapies in an effort to gain greater control of the disease. These transitions could include moving from an oral treatment to an injectable medicine, such as a glucagon-like peptide 1 receptor agonist (GLP-1) or insulin. Which treatment would be best? What factors influence a health-care professional\'s decision in choosing an injectable option? What factors influence the patient\'s acceptance of that decision?
Understanding perspectives of both the patient and healthcare professional: How can health-care providers gain a better understanding of the patient\'s journey? What are the key questions they and the patient can ask each other? Can real-world perspectives increase understanding of why some patients accept transition from orals to injectables to insulin, while others are less enthusiastic?
Financial terms:
Latest news:
